Business Context and Reporting Period
Company: ChromaDex Corporation (Note: Request metadata listed "Niagen Bioscience, Inc.", but the filing identifies the registrant as ChromaDex Corporation).
Filing Type: Form 8-K (Current Report)
Date of Report: April 22, 2010 (Event Date); Signed April 26, 2010.
Primary Event: Entry into a Material Definitive Agreement for a private placement of equity securities and associated corporate governance changes.
Key Financial Metrics and Transaction Details
- Private Placement Proceeds: $3,674,997.62 from the sale of 26,249,983 shares at $0.14 per share.
- Warrant Terms: Warrants issued to purchase an equal number of shares (26,249,983) at an exercise price of $0.21 per share.
- Potential Total Proceeds: Up to $9,187,494.05 if all warrants are exercised for cash.
- Share Count Impact: Outstanding shares to increase from 28,838,216 to 55,088,199 immediately post-closing.
- Dilution: Private Placement Shares represent ~42.8% of outstanding stock; combined with Warrants, they represent ~60.0% on a fully diluted basis.
- Use of Proceeds: General corporate purposes, investor relations, and repayment of approximately $1.2 million "Due to officers."
Material Changes and Corporate Actions
- Board Composition: Thomas Varvaro and Kevin Jaksch to resign from the Board. Michael Brauser and Glenn Halpryn (designees of Subscribers) to be appointed.
- Authorized Stock: Proposal to increase authorized common stock from 50 million to 150 million shares (subject to stockholder approval).
- Management Compensation: New employment agreements for Frank Jaksch, Jr. and Thomas Varvaro. Post-closing option grants totaling ~7.2% of fully diluted stock for directors and key management.
- Strategic Partnership: Exclusive worldwide license secured for the botanical compound pterostilbene from the University of Mississippi and USDA.
Conditions, Risks, and Outlook
- Closing Conditions: Transaction is contingent upon stockholder approval of the charter amendment, resignation of current directors, appointment of new directors, and execution of employment agreements.
- Price Protection: Subscription Agreement includes a mechanism to issue additional shares if the Company issues stock at a lower price within three years.
- Registration Obligations: Company must file registration statements for Warrant Shares within 90 days and keep them effective for three years. Filing of other registration statements is restricted without Subscriber consent.
- Uncertainty: No guarantee that the Private Placement will close or that Subscribers will exercise Warrants.
Investor Verification Checklist
- Verify the outcome of the stockholder vote regarding the increase in authorized shares and the Board composition changes.
- Confirm the actual closing date of the Private Placement and the receipt of the $3.67 million initial proceeds.
- Monitor the filing of the registration statement for Warrant Shares within the required 90-day window.
- Review the specific terms of the pterostilbene license agreement (Exhibit 99.1) for revenue potential and milestones.
- Assess the impact of the $1.2 million repayment to officers on immediate liquidity and working capital.